Skip to content

Probiscend

Navigating Justice, Empowering Voices

  • Institutional Review Boards
  • Medicare Part D
  • Prescription Monitoring Programs
  • Food Drug and Cosmetic Act
  • Controlled Substances Act
  • Patient Safety Organization Standards
  • Telemedicine Regulation

Probiscend

Navigating Justice, Empowering Voices

  • Institutional Review Boards
  • Medicare Part D
  • Prescription Monitoring Programs
  • Food Drug and Cosmetic Act
  • Controlled Substances Act
  • Patient Safety Organization Standards
  • Telemedicine Regulation
Food Drug and Cosmetic Act
March 5, 2024 ProbiScend Team

Understanding Patent Term Extensions for Drugs in Legal Contexts

Patent term extensions for drugs serve as a vital mechanism to ensure innovation is adequately rewarded amid lengthy regulatory approval

Read More
New Drug Application Process
March 5, 2024 ProbiScend Team

Understanding the Common Reasons for NDA Rejection in Legal Agreements

Navigating the complexities of the New Drug Application (NDA) process requires meticulous attention to detail and strict adherence to regulatory

Read More
Biologics License Application
March 5, 2024 ProbiScend Team

Legal Considerations and Best Practices in Stability Testing for Biologics

Stability testing for biologics is a critical component in ensuring the safety, efficacy, and quality of complex therapeutic products throughout

Read More
Orphan Drug Act
March 4, 2024 ProbiScend Team

Understanding the Orphan Drug Designation Application Steps in Legal Contexts

The Orphan Drug Act has significantly transformed the landscape of rare disease treatment, offering incentives to develop therapies for conditions

Read More
Abbreviated New Drug Application
March 4, 2024 ProbiScend Team

The Impact of Patent Litigation on ANDA: Legal Challenges and Industry Implications

Patent litigation plays a significant role in shaping the landscape of generic drug development and approval processes. Specifically, the impact

Read More
Food Drug and Cosmetic Act
March 4, 2024 ProbiScend Team

Understanding the Hatch-Waxman Act Provisions and Their Legal Significance

The Hatch-Waxman Act, a pivotal component of the Food, Drug, and Cosmetic Act, fundamentally reshapes pharmaceutical patent rights and drug

Read More
Biologics License Application
March 4, 2024 ProbiScend Team

Essential Aspects of Biologic Product Characterization in Legal Contexts

Biologic product characterization is a fundamental component of the Biologics License Application process, ensuring the safety, efficacy, and quality of

Read More
New Drug Application Process
March 4, 2024 ProbiScend Team

Navigating Regulatory Challenges in NDA Submission and Approval Processes

Navigating the regulatory landscape of the New Drug Application (NDA) process presents numerous challenges for pharmaceutical developers and legal professionals

Read More
Orphan Drug Act
March 4, 2024 ProbiScend Team

Understanding the Role of the FDA in Orphan Drug Development and Approval

The role of the FDA in orphan drugs is pivotal to ensuring that patients with rare diseases gain access to

Read More
Abbreviated New Drug Application
March 4, 2024 ProbiScend Team

Understanding the Patent Certification Types in ANDA Applications

Patent certification plays a critical role in the approval process of Abbreviated New Drug Applications (ANDAs), influencing market exclusivity and

Read More
  • ← Previous
  • Next →
  • About
  • Contact Us
  • Privacy Policy
  • Disclaimer
  • Terms & Conditions